Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity

Biochemical and Biophysical Research Communications

Volumn 351, Issue 2, 2006, Pages 499-506

  Brazda, Vaclav ^a   Muller, Petr ^b   Brozkova, Kristyna ^b   Vojtesek, Borivoj ^b  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

DNA binding; p53 mutants; Protein DNA complex

Indexed keywords

DNA BINDING PROTEIN; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DNA BINDING; DNA PROTEIN COMPLEX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; TEMPERATURE; TRANSCRIPTION INITIATION; WILD TYPE;

CELL LINE, TUMOR; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; TEMPERATURE; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750531043     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.10.065     Document Type: Article

References (36)

1. Bullock A.N., and Fersht A.R. Rescuing the function of mutant p53. Nat. Rev. Cancer 1 (2001) 68-76
2. Sigal A., and Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60 (2000) 6788-6793
3. Hupp T.R., Lane D.P., and Ball K.L. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 352 Pt 1 (2000) 1-17
4. Soussi T., Kato S., Levy P.P., and Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum. Mutat. 25 (2005) 6-17
5. Beroud C., and Soussi T. p53 gene mutation: software and database. Nucleic Acids Res. 26 (1998) 200-204
6. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., and Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1 (1992) 45-49
7. Jagelska E., Brazda V., Pospisilova S., Vojtesek B., and Palecek E. New ELISA technique for analysis of p53 protein/DNA binding properties. J. Immunol. Methods 267 (2002) 227
8. Brazda V., Palecek J., Pospisilova S., Vojtesek B., and Palecek E. Specific modulation of p53 binding to consensus sequence within supercoiled DNA by monoclonal antibodies. Biochem. Biophys. Res. Commun. 267 (2000) 934-939
9. Palecek E., Brazda V., Jagelska E., Pecinka P., Karlovska L., and Brazdova M. Enhancement of p53 sequence-specific binding by DNA supercoiling. Oncogene 23 (2004) 2119-2127
10. Milner J. Flexibility: the key to p53 function?. Trends Biochem. Sci. 20 (1995) 49-51
11. Bullock A.N., Henckel J., DeDecker B.S., Johnson C.M., Nikolova P.V., Proctor M.R., Lane D.P., and Fersht A.R. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. USA 94 (1997) 14338-14342
12. Hansen S., Hupp T.R., and Lane D.P. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group. J. Biol. Chem. 271 (1996) 3917-3924
13. Willis A., Jung E.J., Wakefield T., and Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23 (2004) 2330-2338
14. Bykov V.J., Selivanova G., and Wiman K.G. Small molecules that reactivate mutant p53. Eur. J. Cancer 39 (2003) 1828-1834
15. Aguilar F., Hussain S.P., and Cerutti P. Aflatoxin B1 induces the transversion of G → T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA 90 (1993) 8586-8590
16. Friedler A., DeDecker B.S., Freund S.M., Blair C., Rudiger S., and Fersht A.R. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation". J. Mol. Biol. 336 (2004) 187-196
17. Bullock A.N., Henckel J., and Fersht A.R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19 (2000) 1245-1256
18. Friedler A., Veprintsev D.B., Hansson L.O., and Fersht A.R. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J. Biol. Chem. 278 (2003) 24108-24112
19. Sambrook J., Fritsch E.F., and Maniatis T. Molecular Cloning: Laboratory Manual (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
20. Pospisilova S., Brazda V., Kucharikova K., Luciani M.G., Hupp T.R., Skladal P., Palecek E., and Vojtesek B. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2. Biochem. J. 378 (2004) 939-947
21. Stephen C.W., Helminen P., and Lane D.P. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J. Mol. Biol. 248 (1995) 58-78
22. Milner J. Structures and functions of the tumor suppressor p53. Pathol. Biol. (Paris) 45 (1997) 797-803
23. Gannon J.V., Greaves R., Iggo R., and Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9 (1990) 1595-1602
24. Midgley C.A., Fisher C.J., Bartek J., Vojtesek B., Lane D., and Barnes D.M. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J. Cell Sci. 101 Pt 1 (1992) 183-189
25. Fredersdorf S., Milne A.W., Hall P.A., and Lu X. Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am. J. Pathol. 148 (1996) 825-835
26. Muller P., Ceskova P., and Vojtesek B. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J. Biol. Chem. 280 (2005) 6682-6691
27. Wang P.L., Sait F., and Winter G. The 'wildtype' conformation of p53: epitope mapping using hybrid proteins. Oncogene 20 (2001) 2318-2324
28. Halazonetis T.D., Davis L.J., and Kandil A.N. Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. EMBO J. 12 (1993) 1021-1028
29. Arrowsmith C.H., and Morin P. New insights into p53 function from structural studies. Oncogene 12 (1996) 1379-1385
30. Hupp T.R., and Lane D.P. Allosteric activation of latent p53 tetramers. Curr. Biol. 4 (1994) 865-875
31. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., and Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. USA 100 (2003) 8424-8429
32. Joerger A.C., Ang H.C., Veprintsev D.B., Blair C.M., and Fersht A.R. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J. Biol. Chem. (2005)
33. Maurici D., Monti P., Campomenosi P., North S., Frebourg T., Fronza G., and Hainaut P. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20 (2001) 3533-3540
34. Issaeva N., Friedler A., Bozko P., Wiman K.G., Fersht A.R., and Selivanova G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl. Acad. Sci. USA 100 (2003) 13303-13307
35. Ohnishi T., Ohnishi K., and Takahashi A. Glycerol restores heat-induced p53-dependent apoptosis of human glioblastoma cells bearing mutant p53. BMC Biotechnol. 2 (2002) 6
36. Ohnishi K., Ota I., Takahashi A., Yane K., Matsumoto H., and Ohnishi T. Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck. Apoptosis 7 (2002) 367-372